$4.19
0.040.96%
At close: May 20, 5:00 PM EST
$4.19
N/A
After Hours: 4:00 PM EST
Atea Pharmaceuticals Inc Analyst Ratings
AVIRNASDAQ
Atea Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:AVIR | Benzinga
Atea Pharmaceuticals Inc has a consensus price target of $8 based on the ratings of 3 analysts. The high is $10 issued by Evercore ISI Group on March 9, 2026. The low is $6 issued by Morgan Stanley on April 11, 2025. The 3 most-recent analyst ratings were released by Evercore ISI Group, Morgan Stanley, and Morgan Stanley on March 9, 2026, April 11, 2025, and August 13, 2024, respectively. With an average price target of $7.63 between Evercore ISI Group, Morgan Stanley, and Morgan Stanley, there's an implied 82.02% upside for Atea Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Evercore ISI Group
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for Atea Pharmaceuticals
Loading calendar...
FAQ
What is the target price for Atea Pharmaceuticals (AVIR) stock?
The latest price target for Atea Pharmaceuticals (NASDAQ:AVIR) was reported by Evercore ISI Group on March 9, 2026. The analyst firm set a price target for $10.00 expecting AVIR to rise to within 12 months (a possible 138.66% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Atea Pharmaceuticals (AVIR)?
The latest analyst rating for Atea Pharmaceuticals (NASDAQ:AVIR) was provided by Evercore ISI Group, and Atea Pharmaceuticals maintained their outperform rating.
When was the last upgrade for Atea Pharmaceuticals (AVIR)?
The last upgrade for Atea Pharmaceuticals Inc happened on August 13, 2024 when Morgan Stanley raised their price target to $6.88. Morgan Stanley previously had an underweight for Atea Pharmaceuticals Inc.
When was the last downgrade for Atea Pharmaceuticals (AVIR)?
The last downgrade for Atea Pharmaceuticals Inc happened on August 10, 2023 when JP Morgan changed their price target from N/A to N/A for Atea Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Atea Pharmaceuticals (AVIR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atea Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atea Pharmaceuticals was filed on March 9, 2026 so you should expect the next rating to be made available sometime around March 9, 2027.
Is the Analyst Rating Atea Pharmaceuticals (AVIR) correct?
While ratings are subjective and will change, the latest Atea Pharmaceuticals (AVIR) rating was a maintained with a price target of $6.00 to $10.00. The current price Atea Pharmaceuticals (AVIR) is trading at is $4.19, which is out of the analyst’s predicted range.
